ADGM
Adagio Medical Holdings, Inc.
$0.7450
-3.50%
$16.5M
No data for this timeframe.
Vol
Market Cap$16.5M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders9 funds
Inst. Value$3.0M
Inst. Activity2 buys / 0 sells
SEC Reports5
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0002006986·Prev Close $0.7720
Recent Activity
May 21, 2026
SEC
Adagio Medical announced submission of a Premarket Approval (PMA) application to the FDA for its vCLAS Ventricular Ablat
8-K — Impact 7/10
May 12, 2026
SEC
Adagio Medical reported Q1 2026 net loss of $7.0M ($0.31/share), beating the Street consensus of $0.36/share loss, with
8-K — Impact 6/10
Apr 27, 2026
SEC
Adagio Medical announced positive pivotal results from its FULCRUM-VT IDE trial for the vCLAS Ventricular Ablation Syste
8-K — Impact 8/10
Mar 6, 2026
Insider
Kaster Deborah was granted 490,500 shares
Chief Financial Officer
Mar 6, 2026
Insider
Usen Todd was granted 800,000 shares
Chief Executive Officer
Inst.
VANGUARD GROUP INC — DOUBLED
79,451 shares ($82.6K)
Inst.
BANK OF AMERICA CORP — DOUBLED
11,494 shares ($12.0K)
May 14, 2026
earnings_calendar
ADGM Q1 2026 Earnings Scheduled — 2026-05-14
Price Targets
$3.33
+347.4% upside
Strong Buy
Current $0.7450
Low $3.00
Median $3.00
High $4.00
3 analysts
$3.00
$4.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | LUCID CAPITAL MARKETS | INITIATE | Buy |
| Apr 14, 2026 | Piper Sandler | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.27 ▲ +11.5% | $-0.27 — $-0.27 | 2 | |
| Next Q | $-0.22 ▲ +32.3% | $-0.28 — $-0.16 | 2 | |
| Current FY | $-0.98 ▲ +22.5% | $-1.15 — $-0.81 | 35% YoY | 2 |
| Next FY | $-1.35 ▲ +20.4% | $-2.33 — $-0.51 | -38% YoY | 3 |
Latest Reports
BULLISH
8-K
7/10
Adagio Medical announced submission of a Premarket Approval (PMA) application to the FDA for its vCLAS Ventricular Ablat
May 21, 2026
BULLISH
8-K
6/10
Adagio Medical reported Q1 2026 net loss of $7.0M ($0.31/share), beating the Street consensus of $0.36/share loss, with
May 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ADAGE CAPITAL PARTNERS GP, | $1.4M | ADD |
| Alyeska Investment Group, L.P. | $1.3M | — |
| VANGUARD FIDUCIARY TRUST CO | $61.8K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $45.5K | — |
| TORONTO DOMINION BANK | $28.8K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 6, 2026 | Kaster Deborah | A | $0.00 |
| Mar 6, 2026 | Usen Todd | A | $0.00 |
9 institutional holders with $3.0M total value (2,566,058 shares) as of 2026-Q1. Top holders: ADAGE, Alyeska, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,258,501 | $1.4M | 49.0% | ADD +28.9% |
| 2 | Alyeska Investment Group, L.P. | 1,159,615 | $1.3M | 45.2% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 53,782 | $61.8K | 2.1% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 39,608 | $45.5K | 1.5% | — |
| 5 | TORONTO DOMINION BANK | 25,000 | $28.8K | 1.0% | ADD +54.4% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 16,557 | $19.0K | 0.6% | — |
| 7 | BANK OF AMERICA CORP /DE/ | 12,857 | $14.8K | 0.5% | DOUBLED +39534.5% |
| 8 | MORGAN STANLEY | 137 | $158.00 | 0.0% | — |
| 9 | CITIGROUP INC | 1 | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 33,078 | 79,451 | +140.2% | $82.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 29 | 11,494 | +39534.5% | $12.0K | 2025-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADD | 821,261 | 1,058,501 | +28.9% | $2.1M | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 12,559 | 83 | -99.3% | $161.00 | 2025-Q3 |
| TORONTO DOMINION BANK | ADD | 20,000 | 30,875 | +54.4% | $24.5K | 2025-Q1 |
| UBS Group AG | DOUBLED | 291 | 1,409 | +384.2% | $1.5K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 19 | 29 | +52.6% | $30.00 | 2024-Q4 |
2 unique insiders with 2 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | Kaster Deborah | Chief Financial Officer | AWARD | 490,500 | — | — |
| Mar 6, 2026 | Usen Todd | Chief Executive Officer | AWARD | 800,000 | — | — |
5 SEC filing reports analyzed. Sentiment: 4 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
BULLISH
8-K
7/10
Adagio Medical announced submission of a Premarket Approval (PMA) application to the FDA for its vCL
May 21, 2026
BULLISH
8-K
6/10
Adagio Medical reported Q1 2026 net loss of $7.0M ($0.31/share), beating the Street consensus of $0.
May 12, 2026
BULLISH
8-K
8/10
Adagio Medical announced positive pivotal results from its FULCRUM-VT IDE trial for the vCLAS Ventri
Apr 27, 2026
BULLISH
8-K
7/10
Adagio Medical received FDA Investigational Device Exemption (IDE) approval to expand its FULCRUM-VT
Apr 8, 2026
BEARISH
EFFECT
7/10
Adagio Medical Holdings has two S-3 shelf registration statements (333-284263 and 333-284266) that b
Apr 6, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$3.33 mean target
+347.4% upside
Strong Buy (1.33)
$3.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $0.7450 |
| Target Low | $3.00 |
| Target Mean | $3.33 |
| Target Median | $3.00 |
| Target High | $4.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.27 | $-0.27 | $-0.27 | — | +11.5% | 1↑ 0↓ | $0.0B | — | 2 |
| Next Q 2026-09-30 |
$-0.22 | $-0.28 | $-0.16 | — | +32.3% | — | $0.0B | — | 2 |
| Current FY 2026-12-31 |
$-0.98 | $-1.15 | $-0.81 | 35.1% | +22.5% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-1.35 | $-2.33 | $-0.51 | -37.8% | +20.4% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.270 | |
| 7d ago | $-0.270 | |
| 30d ago | $-0.305 | +0.035 |
| 60d ago | $-0.230 | -0.040 |
| 90d ago | $-0.240 | -0.030 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | LUCID CAPITAL MARKETS | INITIATE | — | Buy |
| Apr 14, 2026 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
earnings_calendar
ADGM Q1 2026 Earnings Scheduled — 2026-05-14
Apr 6, 2026
earnings_calendar
ADGM Q4 2025 Earnings Scheduled — 2026-04-06